UBS AG assumed coverage on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in a research report released on Wednesday morning, The Fly reports. The firm issued a reduce rating on the biotechnology company’s stock.
A number of other analysts have also issued reports on RDHL. HC Wainwright set a $33.00 price target on Redhill Biopharma and gave the company a buy rating in a report on Wednesday, July 26th. Roth Capital set a $27.00 price target on Redhill Biopharma and gave the company a buy rating in a report on Monday, July 31st. Zacks Investment Research lowered Redhill Biopharma from a hold rating to a sell rating in a report on Saturday, July 29th. Finally, FBR & Co reiterated a buy rating on shares of Redhill Biopharma in a report on Friday, June 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Redhill Biopharma has a consensus rating of Hold and an average price target of $23.69.
Redhill Biopharma (NASDAQ RDHL) traded up 2.46% during midday trading on Wednesday, reaching $8.76. The company’s stock had a trading volume of 49,649 shares. The company’s 50-day moving average is $8.71 and its 200 day moving average is $9.38. Redhill Biopharma has a 12-month low of $8.16 and a 12-month high of $15.27. The firm’s market cap is $150.35 million.
Redhill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The company had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $0.34 million. Equities analysts forecast that Redhill Biopharma will post ($2.36) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/09/16/redhill-biopharma-ltd-rdhl-research-coverage-started-at-ubs-ag.html.
A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its holdings in Redhill Biopharma by 13.6% during the second quarter. Bank of New York Mellon Corp now owns 12,005 shares of the biotechnology company’s stock worth $103,000 after buying an additional 1,440 shares during the period. Oppenheimer & Co. Inc. lifted its holdings in Redhill Biopharma by 10.8% during the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after buying an additional 2,500 shares during the period. D.A. Davidson & CO. lifted its holdings in Redhill Biopharma by 10.0% during the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after buying an additional 4,000 shares during the period. Penserra Capital Management LLC lifted its holdings in Redhill Biopharma by 75.0% during the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock worth $171,000 after buying an additional 7,647 shares during the period. Finally, Family Management Corp lifted its holdings in Redhill Biopharma by 51.5% during the second quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after buying an additional 8,750 shares during the period. Institutional investors own 10.99% of the company’s stock.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.